Whitehawk Therapeutics (WHWK) Gross Profit (2021 - 2025)

Whitehawk Therapeutics (WHWK) has 5 years of Gross Profit data on file, last reported at $6.4 million in Q1 2025.

• Quarterly Gross Profit rose 35.82% year-over-year to $6.4 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $6.4 million (down 72.19% YoY) and the FY2025 annual result came in at $6.4 million, down 72.19% from the prior year.
• Gross Profit retreated to $6.4 million in Q1 2025 per WHWK's latest filing, from $6.4 million in the prior quarter.
• Across five years, Gross Profit topped out at $14.0 million in Q4 2021 and bottomed at $2.1 million in Q1 2022.
• The 5-year median for Gross Profit is $5.4 million (2023), against an average of $5.6 million.
• The widest annual swing landed in 2022, when Gross Profit slumped 64.25%; it then jumped 150.85% in 2023.
• Tracing WHWK's Gross Profit over 5 years: stood at $14.0 million in 2021, then tumbled by 64.25% to $5.0 million in 2022, then increased by 7.87% to $5.4 million in 2023, then rose by 19.45% to $6.4 million in 2024, then dropped by 0.99% to $6.4 million in 2025.
• Per Business Quant, the three latest WHWK Gross Profit figures stand at $6.4 million (Q1 2025), $6.4 million (Q4 2024), and $6.4 million (Q3 2024).

Peer Comparison